ULURU Inc. provided an update on recent Altrazeal(R) developments. The international marketing network for Altrazeal(R) has been expanded through the appointment of exclusive licensees for 17 Middle East and North African markets. Together with previously signed agreements for Saudi Arabia, Afghanistan and the United Arab Emirates these agreements cover a population of approximately 475 million people.

The large markets of Egypt, Iraq, Algeria, Morocco and Sudan are covered by the most recent agreements. In addition, Altrazeal(R) has received regulatory approval in Singapore after an extensive review process. This is an important milestone as this is the first Asian market to approve Altrazeal.

With this approval Altrazeal(R) is now approved in the United States, the European Union, Australia, New Zealand, South Africa, Singapore and Afghanistan. Altrazeal(R) is also marketed in numerous other markets which respect the CE Mark or allow exemptions to the registration process.